(Q37356528)

19 August 2017

1 reference

title

Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach (English)

1 reference

19 August 2017

0 references

1 reference

personalized medicine

1 reference

Saskia Vosslamber

1

1 reference

PubMed ID

19102719

19 August 2017

Lisa G M van Baarsen

series ordinal

2

1 reference

PubMed ID

19102719

19 August 2017

Cornelis L Verweij

series ordinal

3

1 reference

19 August 2017

1 January 2009

1 reference

19 August 2017

1 reference

19 August 2017

10

1 reference

19 August 2017

1

1 reference

19 August 2017

97-108

1 reference

Defining interferon beta response status in multiple sclerosis patients.

19 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Clinical viral infections and multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Interferon-inducible antiviral effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Functional role of type I and type II interferons in antiviral defense

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

How cells respond to interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

IFN regulation and functions in myeloid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

IRF family of transcription factors as regulators of host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Interferon signalling network in innate defence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

The interferon-inducible Stat2:Stat1 heterodimer preferentially binds in vitro to a consensus element found in the promoters of a subset of interferon-stimulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

New aspects of IFN-alpha/beta signalling in immunity, oncogenesis and bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Functional relevance of the conserved DNA-binding domain of STAT2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Identification of a nuclear Stat1 protein tyrosine phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Intermittent interferonemia and interferon responses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Understanding autoimmune mechanisms in multiple sclerosis using gene expression microarrays: treatment effect and cytokine-related pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Genomic effects of IFN-beta in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Novel interferon-beta-induced gene expression in peripheral blood cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Gene expression profiles reveal homeostatic dynamics during interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Transcription-based prediction of response to IFNbeta using supervised computational methods

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Biologic Effects of Interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.97

21 January 2018

Identifiers

DOI

10.2217/14622416.10.1.97

1 reference

19 August 2017

1 reference

PubMed ID

19102719